The Audio Journal of Oncology talks with:
Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell’Immacolata, Rome
And with:
Elaine R. Mardis, PhD FAACR, Co-Executive Director of the Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Rasmussen Nationwide Foundation Endowed Chair in Genomic Medicine, Professor of Pediatrics, Ohio State University College of Medicine, Columbus OH, USA.
CHICAGO, USA—Using a combination of tissue biopsy together with liquid biopsy seems to be the best way of providing samples for genomic profiling when you need to plan treatment for patients with advanced solid tumors. This is the clear implication of findings from the phase two multicenter ROME trial reported at 2025 Annual Meeting of the American Association for Cancer Research (AACR).
These two modalities of biopsy collect tissues from different parts of the tumor. So, an actionable mutation may be found by one method, and missed by another. But in cases where both methods detect the same targetable molecular marker, the strategy for treatment is now looking much clearer, according to the lead study author Paolo Marchetti, Scientific Director of the Istituto Dermatopatico dell’Immacolata in Rome. He’s been talking with our reporter in Chicago, Peter Goodwin, who also spoke with the AACR press briefing moderator Elaine R Mardis PhD FAACR, Co-Executive Director of the Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital, who holds the Chair in Genomic Medicine and is Professor of Pediatrics at Ohio State University College of Medicine in Columbus Ohio.
INTERVIEWS:
- Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell’Immacolata, Rome
- Elaine R. Mardis,PhD FAACR, Co-Executive Director of the Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Rasmussen Nationwide Foundation Endowed Chair in Genomic Medicine, Professor of Pediatrics, Ohio State University College of Medicine, Columbus OH.
- AACR Abstract Title:
Combined tissue and liquid biopsy improves outcomes in advanced solid tumors: an exploratory analysis of the ROME trial.
